Topiramate side effects: what 91,049 FDA adverse event reports show
Drug class
Cytochrome P450 3A4 Inducers, Cytochrome P450 2C19 Inhibitors
Who reports
91,049 reports · 69% serious · 6,839 with death outcome · 78% female
Used for
Topiramate is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ( 1.1 ); adjunctive therapy for the treatment of partial-onset seizures, pri.
What it is
Topiramate is a hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,173 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Hepatic enzyme | 79 | 297.7 212.5–417.0ROR 297.9 · calibrated p 3e-11 ✓ | 124.1 EB05 102.8 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious n=78 · ♀ 100% (drug 78%) · 100% clinician | no trial arm names this drug |
| Visual perseveration | 75 | 231.6 167.6–320.0ROR 231.8 · calibrated p 3e-10 ✓ | 110.8 EB05 91.3 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | ♀ 100% (drug 78%) · 100% clinician | no trial arm names this drug |
| Acute myopia | 62 | 128.8 94.2–176.1ROR 128.9 · calibrated p 3e-8 ✓ | 80.0 EB05 64.6 · IC025 +5.2 3/3 methods agree | Labeled adverse reaction exact term | serious n=60 · ♀ 100% (drug 78%) · 100% clinician | no trial arm names this drug |
| Flat anterior chamber of eye | 60 | 112.1 82.2–152.9ROR 112.2 · calibrated p 9e-8 ✓ | 73.2 EB05 58.9 · IC025 +5.1 3/3 methods agree | Labeled (related wording) related wording | serious n=58 · ♀ 0% (drug 78%) · 100% clinician | no trial arm names this drug |
| Hypocholesterolaemia | 96 | 102.6 80.6–130.7ROR 102.7 · calibrated p 1e-7 ✓ | 69.6 EB05 58.7 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | serious n=95 · ♀ 100% (drug 78%) · 100% clinician | no trial arm names this drug |
| Choroidal effusion | 198 | 74.5 63.4–87.5ROR 74.6 · calibrated p 1e-6 ✓ | 55.8 EB05 49.5 · IC025 +5.4 3/3 methods agree | Labeled (related wording) related wording | serious n=197 · 100% clinician | no trial arm names this drug |
| Neovascularisation | 63 | 73.7 55.4–98.0ROR 73.8 · calibrated p 2e-6 ✓ | 54.7 EB05 44.3 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=63 · ♀ 100% (drug 78%) · 100% clinician | no trial arm names this drug |
| Angle closure glaucoma | 597 | 68.7 62.7–75.3ROR 69.2 · calibrated p 2e-6 ✓ | 52.7 EB05 49.2 · IC025 +5.5 3/3 methods agree | Labeled adverse reaction exact term | serious n=571 | no trial arm names this drug |
| Facet joint syndrome | 622 | 55.5 50.9–60.6ROR 55.9 · calibrated p 7e-6 ✓ | 44.6 EB05 41.7 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=621 · ♀ 100% (drug 78%) · 91% clinician | no trial arm names this drug |
| Multiple-drug resistance | 609 | 55.4 50.7–60.5ROR 55.7 · calibrated p 7e-6 ✓ | 44.5 EB05 41.6 · IC025 +5.3 3/3 methods agree | Reporting / coding artifact | serious n=495 · 100% clinician | no trial arm names this drug |
| Anhidrosis | 73 | 49.3 38.3–63.6ROR 49.4 · calibrated p 2e-5 ✓ | 40.2 EB05 33.0 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=64 · ♀ 0% (drug 78%) | no trial arm names this drug |
| Acidosis hyperchloraemic | 98 | 45.1 36.3–56.0ROR 45.2 · calibrated p 3e-5 ✓ | 37.4 EB05 31.6 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=97 · 100% clinician | no trial arm names this drug |
| Peripheral venous disease | 620 | 41.5 38.1–45.2ROR 41.8 · calibrated p 4e-5 ✓ | 35.1 EB05 32.8 · IC025 +5.0 3/3 methods agree | Labeled (related wording) related wording | serious n=617 · ♀ 100% (drug 78%) · 93% clinician | no trial arm names this drug |
| Medication overuse headache | 130 | 40.5 33.6–48.8ROR 40.5 · calibrated p 6e-5 ✓ | 34.2 EB05 29.6 · IC025 +4.6 3/3 methods agree | Labeled (related wording) related wording | serious n=120 · ♀ 100% (drug 78%) · 100% clinician | no trial arm names this drug |
| Phonophobia | 66 | 37.9 29.2–49.2ROR 37.9 · calibrated p 9e-5 ✓ | 32.3 EB05 26.2 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=63 · ♀ 0% (drug 78%) · 100% clinician | no trial arm names this drug |
| Infantile spasms | 101 | 37.1 30.1–45.8ROR 37.2 · calibrated p 9e-5 ✓ | 31.8 EB05 26.9 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=101 · ♀ 0% (drug 78%) | no trial arm names this drug |
| Hypohidrosis | 69 | 36.6 28.4–47.2ROR 36.6 · calibrated p 1e-4 ✓ | 31.3 EB05 25.6 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=59 · 100% consumer | no trial arm names this drug |
| Overlap syndrome | 94 | 35.6 28.6–44.3ROR 35.6 · calibrated p 1e-4 ✓ | 30.7 EB05 25.8 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=94 · ♀ 100% (drug 78%) · 100% clinician | no trial arm names this drug |
| Onychomadesis | 565 | 35.5 32.5–38.8ROR 35.7 · calibrated p 1e-4 ✓ | 30.7 EB05 28.7 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=562 · ♀ 100% (drug 78%) · 90% clinician | no trial arm names this drug |
| Blepharospasm | 828 | 34.8 32.3–37.4ROR 35.1 · calibrated p 1e-4 ✓ | 30.2 EB05 28.5 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=798 · ♀ 100% (drug 78%) | no trial arm names this drug |
| Myopia | 303 | 33.1 29.3–37.3ROR 33.2 · calibrated p 2e-4 ✓ | 28.9 EB05 26.2 · IC025 +4.6 3/3 methods agree | Labeled adverse reaction exact term | serious n=285 | no trial arm names this drug |
| Rheumatic fever | 524 | 30.8 28.1–33.7ROR 30.9 · calibrated p 2e-4 ✓ | 27.1 EB05 25.2 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=524 · ♀ 100% (drug 78%) · 93% clinician | no trial arm names this drug |
| Cleft lip | 106 | 30.7 25.1–37.6ROR 30.8 · calibrated p 3e-4 ✓ | 27.0 EB05 23.0 · IC025 +4.3 3/3 methods agree | Labeled adverse reaction exact term | serious n=106 · ♀ 0% (drug 78%) | no trial arm names this drug |
| Myoclonic epilepsy | 175 | 30.4 26.0–35.6ROR 30.5 · calibrated p 3e-4 ✓ | 26.8 EB05 23.6 · IC025 +4.4 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=173 | no trial arm names this drug |
| Renal tubular acidosis | 258 | 30.2 26.5–34.4ROR 30.3 · calibrated p 3e-4 ✓ | 26.6 EB05 24.0 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=257 · 100% clinician | no trial arm names this drug |
| Cleft lip and palate | 127 | 28.6 23.8–34.4ROR 28.6 · calibrated p 4e-4 ✓ | 25.4 EB05 21.9 · IC025 +4.2 3/3 methods agree | Labeled (related wording) related wording | serious n=127 · ♀ 0% (drug 78%) | no trial arm names this drug |
| Choroidal detachment | 62 | 28.4 21.8–37.0ROR 28.4 · calibrated p 4e-4 ✓ | 25.1 EB05 20.3 · IC025 +4.0 3/3 methods agree | Labeled adverse reaction exact term | serious n=62 · 100% clinician | no trial arm names this drug |
| Change in seizure presentation | 71 | 27.4 21.4–35.0ROR 27.4 · calibrated p 5e-4 ✓ | 24.3 EB05 19.9 · IC025 +4.0 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=69 · ♀ 0% (drug 78%) · 100% clinician | no trial arm names this drug |
| Breast cancer stage iii | 659 | 25.7 23.8–27.9ROR 25.9 · calibrated p 6e-4 ✓ | 23.2 EB05 21.7 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=659 · ♀ 100% (drug 78%) · 93% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody positive | 707 | 24.9 23.1–26.9ROR 25.1 · calibrated p 7e-4 ✓ | 22.5 EB05 21.1 · IC025 +4.3 3/3 methods agree | Lab value / disease marker | serious PRR 19.1 · ♀ 100% (drug 78%) · 92% clinician | no trial arm names this drug |
| Lupus vulgaris | 115 | 24.1 19.9–29.2ROR 24.1 · calibrated p 9e-4 ✓ | 21.8 EB05 18.6 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=115 · ♀ 100% (drug 78%) · 100% clinician | no trial arm names this drug |
| Atonic seizures | 74 | 23.1 18.2–29.3ROR 23.1 · calibrated p 0.001 ✓ | 20.9 EB05 17.2 · IC025 +3.8 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=69 | no trial arm names this drug |
| Hyperammonaemic encephalopathy | 157 | 22.8 19.3–26.8ROR 22.8 · calibrated p 0.001 ✓ | 20.7 EB05 18.1 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=156 · ♀ 56% (drug 78%) · 100% clinician | no trial arm names this drug |
| Onychomycosis | 400 | 22.7 20.5–25.1ROR 22.8 · calibrated p 0.001 ✓ | 20.6 EB05 19.0 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=396 · ♀ 100% (drug 78%) · 91% clinician | no trial arm names this drug |
| Finger deformity | 429 | 21.9 19.8–24.2ROR 22.0 · calibrated p 0.001 ✓ | 20.0 EB05 18.5 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=426 · ♀ 100% (drug 78%) | no trial arm names this drug |
| Duodenal ulcer perforation | 646 | 21.8 20.1–23.6ROR 21.9 · calibrated p 0.001 ✓ | 19.9 EB05 18.6 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious PRR 16.8 · ♀ 100% (drug 78%) · 92% clinician | no trial arm names this drug |
| Complex partial seizures | 99 | 21.7 17.7–26.7ROR 21.7 · calibrated p 0.001 ✓ | 19.8 EB05 16.7 · IC025 +3.8 3/3 methods agree | Labeled (related wording) related wording | serious n=97 | no trial arm names this drug |
| Dislocation of vertebra | 194 | 21.5 18.6–25.0ROR 21.6 · calibrated p 0.001 ✓ | 19.7 EB05 17.5 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=194 · ♀ 100% (drug 78%) · 100% clinician | no trial arm names this drug |
| Heat stroke | 121 | 20.2 16.8–24.3ROR 20.2 · calibrated p 0.002 ✓ | 18.6 EB05 15.9 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=120 · ♀ 0% (drug 78%) · 100% clinician | no trial arm names this drug |
| Self injurious behaviour | 253 | 20.1 17.7–22.8ROR 20.1 · calibrated p 0.002 ✓ | 18.5 EB05 16.6 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=253 | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Seizure | 6,743 | 8.28.0–8.3 | signal |
| Suicidality | 3,833 | 3.63.5–3.7 | signal |
| Depression | 4,246 | 3.53.4–3.6 | signal |
| Extrapyramidal | 1,005 | 2.22.1–2.3 | signal |
| Fall / fracture | 3,020 | 1.81.8–1.9 | raised |
| Liver injury | 2,223 | 1.71.6–1.8 | raised |
| Hyperglycaemia / diabetes | 2,271 | 1.51.5–1.6 | raised |
| Rhabdomyolysis / myopathy | 521 | 1.51.4–1.6 | raised |
| Pancreatitis | 491 | 1.41.3–1.5 | raised |
| Venous thromboembolism | 1,285 | 1.41.3–1.4 | raised |
| Anaphylaxis / angioedema | 723 | 1.31.2–1.4 | raised |
| Severe cutaneous reaction | 396 | 1.21.1–1.4 | raised |
| Serious infection | 4,075 | 1.21.2–1.3 | raised |
| Tendon disorder | 162 | 1.00.8–1.1 | no difference |
| Kidney injury | 1,898 | 1.00.9–1.0 | no difference |
| Arrhythmia / qt | 768 | 0.90.9–1.0 | lower than other drugs |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 10,533 | 1.8 1.8–1.9ROR 1.9 · calibrated p 0.900 | 1.8 EB05 1.8 · IC025 +0.8 | Reporting / coding artifact | age-adj. PRR 2.1 · serious PRR 3.0 | no trial arm names this drug |
| Off label use (used outside approved label) | 7,635 | 2.0 2.0–2.0ROR 2.1 · calibrated p 0.992 | 2.0 EB05 2.0 · IC025 +1.0 | Reporting / coding artifact | age-adj. PRR 2.0 · serious PRR 2.4 | no trial arm names this drug |
| Headache | 6,681 | 2.4 2.4–2.5ROR 2.5 · calibrated p 0.796 | 2.4 EB05 2.4 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.1 · serious PRR 2.8 | no trial arm names this drug |
| Nausea | 6,018 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.819 | 1.7 EB05 1.7 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.9 | no trial arm names this drug |
| Fatigue (tiredness) | 5,505 | 1.6 1.6–1.6ROR 1.6 · calibrated p 0.736 | 1.6 EB05 1.6 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.7 | no trial arm names this drug |
| Pain | 4,659 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.804 | 1.7 EB05 1.7 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.9 · serious PRR 1.8 | no trial arm names this drug |
| Migraine | 4,586 | 11.5 11.1–11.8ROR 12.0 · calibrated p 0.017 ✓ | 10.9 EB05 10.7 · IC025 +3.4 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 9.2 · serious PRR 12.6 | no trial arm names this drug |
| Dizziness | 4,295 | 2.0 1.9–2.0ROR 2.0 · calibrated p 0.948 | 2.0 EB05 1.9 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 2.0 · serious PRR 2.1 | no trial arm names this drug |
| Seizure | 3,903 | 7.9 7.7–8.2ROR 8.2 · calibrated p 0.061 | 7.7 EB05 7.5 · IC025 +2.9 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 5.4 · serious PRR 6.3 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 3,804 | 1.3 1.3–1.4ROR 1.4 · calibrated p 0.545 | 1.3 EB05 1.3 · IC025 +0.4 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.3 | no trial arm names this drug |
| Vomiting | 3,726 | 1.8 1.7–1.9ROR 1.8 · calibrated p 0.853 | 1.8 EB05 1.8 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.8 | no trial arm names this drug |
| Depression | 3,693 | 3.7 3.6–3.8ROR 3.8 · calibrated p 0.414 | 3.7 EB05 3.6 · IC025 +1.8 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 3.2 · serious PRR 3.6 | no trial arm names this drug |
| Product use in unapproved indication | 3,283 | 3.1 3.0–3.2ROR 3.1 · calibrated p 0.581 | 3.0 EB05 3.0 · IC025 +1.5 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 3.0 · serious PRR 4.4 | no trial arm names this drug |
| Weight increased (weight gain) | 3,096 | 3.2 3.1–3.3ROR 3.3 · calibrated p 0.550 | 3.1 EB05 3.1 · IC025 +1.6 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 3.0 · serious PRR 3.8 | no trial arm names this drug |
| Weight decreased (weight loss) | 3,038 | 2.5 2.4–2.6ROR 2.5 · calibrated p 0.800 | 2.5 EB05 2.4 · IC025 +1.2 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 2.4 · serious PRR 2.4 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Hepatic enzyme — n=79, PRR 297.7
- Visual perseveration — n=75, PRR 231.6
- Hypocholesterolaemia — n=96, PRR 102.6
- Neovascularisation — n=63, PRR 73.7
- Facet joint syndrome — n=622, PRR 55.5
- Anhidrosis — n=73, PRR 49.3
- Acidosis hyperchloraemic — n=98, PRR 45.1
- Phonophobia — n=66, PRR 37.9
- Infantile spasms — n=101, PRR 37.1
- Hypohidrosis — n=69, PRR 36.6
✓ A hand-written Bradford Hill causality assessment exists for this drug: Topiramate ↔ Acute angle-closure glaucoma.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Topiramate?
In FDA FAERS, the most frequently co-reported reaction terms for Topiramate are headache, nausea, fatigue, pain, migraine, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Topiramate have an FDA boxed warning?
No. The FDA label retrieved for Topiramate has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Topiramate causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 0366164b-1846-443d-9564-dbe52d8d9b65, effective 20260708; matched on
openfda.generic_name.exact:"TOPIRAMATE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 5284627 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,213 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
TOPIRAMATE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.